세계의 클라미디아 감염 진단 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 검사 유형별, 감염증 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type of Infections, By End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,174,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,546,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 10,976,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

클라미디아 감염 진단 세계 시장은 2024년에 7억 2,133만 달러로 평가되었습니다. 2030년에는 10억 3,167만 달러에 달하고, 예측 기간 동안 6.12%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

클라미디아 감염증의 원인균인 클라미디아 트라코마티스는 전 세계적으로 가장 널리 퍼진 성병(STI)의 원인 중 하나입니다. 클라미디아는 무증상인 경우가 많아 진단되지 않는 경우가 많아 불임, 골반 내 염증성 질환과 같은 합병증을 유발하고 다른 감염 질환에 걸리기 쉬우며, STI에 대한 인식이 높아지고 특히 15-24세 성적으로 활동적인 사람들 사이에서 STI의 세계적 부담이 증가함에 따라, 적시에 정확한 진단에 대한 수요가 증가하고 있습니다. 적시에 정확한 진단에 대한 수요가 증가하고 있습니다. 시장은 고감도로 잘 알려진 핵산증폭검사(NAAT)와 같이 접근성과 정확성을 높이는 기술 혁신으로 대응해 왔습니다. 중앙 집중식 검사 시설에 의존하고 있음에도 불구하고, 현재 진행 중인 노력은 검사 시간을 개선하고, 검사 범위를 확대하는 데 초점을 맞추고 있으며, 이는 감염병을 억제하기 위한 광범위한 공중보건 전략을 지원하는 데 도움이 되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	7억 2,133만 달러
시장 규모 : 2030년	10억 3,167만 달러
CAGR : 2025-2030년	6.12%
급성장 부문	병원
최대 시장	북미

주요 시장 성장 촉진요인

클라미디아 감염률 상승이 클라미디아 감염 진단 시장을 주도하고 있습니다.

주요 시장 과제

과소 진단과 인식 부족

주요 시장 동향

기술 발전

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 클라미디아 감염 진단 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 검사 유형별(배양 검사, 핵산 증폭 검사(NAAT), 직접 형광 항체 검사, 혈청학적 검사 등)
  • 감염증 유형별(성기 클라미디아 감염증, 직장 클라미디아 감염증, 눈 클라미디아 감염증)
  • 최종사용자별(병원, 전문 클리닉, 진단센터)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 테스트 유형별
  • 감염증 유형별
  • 최종사용자별
  • 지역별

제6장 북미의 클라미디아 감염 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측

제7장 유럽의 클라미디아 감염 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측

제8장 아시아태평양의 클라미디아 감염 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측

제9장 남미의 클라미디아 감염 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측

제10장 중동 및 아프리카의 클라미디아 감염 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병(M&A)
• 제품 출시

제13장 경쟁 구도

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca
• Teva Pharmaceutical Industries Limited
• bioMerieux SA

제14장 전략적 제안

제15장 회사 소개 및 면책조항

LSH

영문 목차

영문목차

The Global Chlamydia Infection Diagnostics Market was valued at USD 721.33 million in 2024 and is projected to reach USD 1031.67 million by 2030, growing at a CAGR of 6.12% during the forecast period. Chlamydia trachomatis, the bacterium responsible for chlamydia infections, is one of the most widespread causes of sexually transmitted infections (STIs) globally. Due to its often asymptomatic nature, chlamydia frequently goes undiagnosed, leading to complications such as infertility, pelvic inflammatory disease, and increased vulnerability to other infections. As awareness grows and the global burden of STIs rises-particularly among sexually active individuals aged 15 to 24-demand for timely, accurate diagnostics has increased. The market has responded with technological innovations that enhance accessibility and accuracy, such as nucleic acid amplification tests (NAATs), which are recognized for their high sensitivity. Despite the reliance on centralized laboratories, ongoing efforts are focused on improving test turnaround and expanding reach through point-of-care technologies, supporting broader public health strategies to contain the infection.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 721.33 Million
Market Size 2030	USD 1031.67 Million
CAGR 2025-2030	6.12%
Fastest Growing Segment	Hospitals
Largest Market	North America

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

The increasing global incidence of chlamydia infections is a major force behind the growth of the diagnostics market. As one of the most commonly reported STIs worldwide, chlamydia poses a significant health risk-particularly among adolescents and young adults who often lack awareness or access to regular testing. The asymptomatic nature of the infection makes it difficult to detect early, increasing the likelihood of long-term reproductive health complications such as infertility and ectopic pregnancies. The heightened focus on routine screening, particularly in high-risk populations, has accelerated the demand for diagnostic tools capable of delivering rapid, accurate results. This has led to the development and deployment of innovative testing methods, bolstering early intervention efforts and supporting global STI control initiatives. Educational campaigns and increased testing infrastructure are further reinforcing the demand for reliable chlamydia diagnostic solutions.

Key Market Challenges

Underdiagnosis and Lack of Awareness

A persistent challenge in the chlamydia diagnostics market is the widespread underdiagnosis of the infection, largely due to its asymptomatic presentation in the majority of cases. Without noticeable symptoms, many individuals remain unaware they are infected and do not seek testing, allowing the disease to spread undetected. This issue is compounded by limited public knowledge about STI risks, as well as cultural stigma surrounding sexual health, which deters open discussion and testing. In some regions, inadequate healthcare infrastructure and insufficient provider emphasis on STI screening further restrict access to diagnostics. These systemic and societal barriers contribute to a gap between infection rates and testing volumes, limiting early treatment and increasing the burden of long-term health complications.

Key Market Trends

Technological Advancements

Advancements in molecular diagnostics are significantly shaping the chlamydia diagnostics market. NAATs, including PCR and LAMP, have become the benchmark for detecting the genetic material of Chlamydia trachomatis, offering unparalleled sensitivity and specificity. These methods enable early detection, which is critical for timely treatment and preventing transmission. Furthermore, smartphone-integrated diagnostic platforms are emerging as accessible, user-friendly tools that facilitate at-home testing. These innovations empower individuals to screen for STIs with greater privacy and convenience. In parallel, serological and antibody-based assays are being utilized to detect historical infections, contributing to epidemiological tracking and broader public health insights. The integration of nucleic acid and serological tests is enhancing diagnostic capability, paving the way for more comprehensive infection profiling and treatment planning.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca
• Teva Pharmaceutical Industries Limited
• bioMerieux SA

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type:

• Culture Test
• Nucleic Acid Amplification Test (NAAT)
• Direct Fluorescent Antibody Test
• Serology Test
• Other

Chlamydia Infection Diagnostics Market, By Type of Infections:

• Genital Chlamydia Infection
• Rectal Chlamydia Infection
• Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User:

• Hospitals
• Specialty Clinics
• Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region:

• North America
• Asia-Pacific
• Europe
• Middle East & Africa
• South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
  • 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
  • 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Test Type
  • 5.3.2. By Type of Infections
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Chlamydia Infection Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Type of Infections
  • 6.2.3. By End User
  • 6.2.4. By Country
    • 6.2.4.1. United States Chlamydia Infection Diagnostics Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
      • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
      • 6.2.4.1.2.1. By Test Type
      • 6.2.4.1.2.2. By Type of Infections
      • 6.2.4.1.2.3. By End User
    • 6.2.4.2. Canada Chlamydia Infection Diagnostics Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
      • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
      • 6.2.4.2.2.1. By Test Type
      • 6.2.4.2.2.2. By Type of Infections
      • 6.2.4.2.2.3. By End User
    • 6.2.4.3. Mexico Chlamydia Infection Diagnostics Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
      • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
      • 6.2.4.3.2.1. By Test
      • 6.2.4.3.2.2. By Type of Infections
      • 6.2.4.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Type of Infections
  • 7.2.3. By End User
  • 7.2.4. By Country
    • 7.2.4.1. France Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
      • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
      • 7.2.4.1.2.1. By Test Type
      • 7.2.4.1.2.2. By Type of Infections
      • 7.2.4.1.2.3. By End User
    • 7.2.4.2. Germany Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
      • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
      • 7.2.4.2.2.1. By Test Type
      • 7.2.4.2.2.2. By Type of Infections
      • 7.2.4.2.2.3. By End User
    • 7.2.4.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
      • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
      • 7.2.4.3.2.1. By Test Type
      • 7.2.4.3.2.2. By Type of Infections
      • 7.2.4.3.2.3. By End User
    • 7.2.4.4. Italy Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
      • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
      • 7.2.4.4.2.1. By Test Type
      • 7.2.4.4.2.2. By Type of Infections
      • 7.2.4.4.2.3. By End User
    • 7.2.4.5. Spain Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
      • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
      • 7.2.4.5.2.1. By Test Type
      • 7.2.4.5.2.2. By Type of Infections
      • 7.2.4.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Type of Infections
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. China Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
      • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
      • 8.2.4.1.2.1. By Test Type
      • 8.2.4.1.2.2. By Type of Infections
      • 8.2.4.1.2.3. By End User
    • 8.2.4.2. India Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
      • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
      • 8.2.4.2.2.1. By Test Type
      • 8.2.4.2.2.2. By Type of Infections
      • 8.2.4.2.2.3. By End User
    • 8.2.4.3. South Korea Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
      • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
      • 8.2.4.3.2.1. By Test Type
      • 8.2.4.3.2.2. By Type of Infections
      • 8.2.4.3.2.3. By End User
    • 8.2.4.4. Japan Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
      • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
      • 8.2.4.4.2.1. By Test Type
      • 8.2.4.4.2.2. By Type of Infections
      • 8.2.4.4.2.3. By End User
    • 8.2.4.5. Australia Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
      • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
      • 8.2.4.5.2.1. By Test Type
      • 8.2.4.5.2.2. By Type of Infections
      • 8.2.4.5.2.3. By End User

9. South America Chlamydia Infection Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Type of Infections
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Chlamydia Infection Diagnostics Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
      • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
      • 9.2.4.1.2.1. By Test Type
      • 9.2.4.1.2.2. By Type of Infections
      • 9.2.4.1.2.3. By End User
    • 9.2.4.2. Argentina Chlamydia Infection Diagnostics Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
      • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
      • 9.2.4.2.2.1. By Test Type
      • 9.2.4.2.2.2. By Type of Infections
      • 9.2.4.2.2.3. By End User
    • 9.2.4.3. Colombia Chlamydia Infection Diagnostics Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
      • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
      • 9.2.4.3.2.1. By Test Type
      • 9.2.4.3.2.2. By Type of Infections
      • 9.2.4.3.2.3. By End User

10. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Type of Infections
  • 10.2.3. By End User
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Chlamydia Infection Diagnostics Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
      • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
      • 10.2.4.1.2.1. By Test Type
      • 10.2.4.1.2.2. By Type of Infections
      • 10.2.4.1.2.3. By End User
    • 10.2.4.2. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
      • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
      • 10.2.4.2.2.1. By Test Type
      • 10.2.4.2.2.2. By Type of Infections
      • 10.2.4.2.2.3. By End User
    • 10.2.4.3. UAE Chlamydia Infection Diagnostics Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
      • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
      • 10.2.4.3.2.1. By Test Type
      • 10.2.4.3.2.2. By Type of Infections
      • 10.2.4.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. F. Hoffmann-La Roche Ltd.
• 13.2. Abbott Laboratories
• 13.3. Hologic, Inc.
• 13.4. Becton, Dickinson and Company
• 13.5. Bio-Rad Laboratories, Inc
• 13.6. Quidel Corporation
• 13.7. DiaSorin SpA
• 13.8. AstraZeneca
• 13.9. Teva Pharmaceutical Industries Limited
• 13.10. bioMerieux SA

14. Strategic Recommendations

15. About us & Disclaimer

관련자료